Harzewski, Erica v. Guidant Corporation

CourtCourt of Appeals for the Seventh Circuit
DecidedJune 5, 2007
Docket06-3752
StatusPublished

This text of Harzewski, Erica v. Guidant Corporation (Harzewski, Erica v. Guidant Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Harzewski, Erica v. Guidant Corporation, (7th Cir. 2007).

Opinion

In the United States Court of Appeals For the Seventh Circuit ____________

No. 06-3752 ERICA HARZEWSKI, et al., on their own behalf and on behalf of all other persons similarly situated, Plaintiffs-Appellants, v.

GUIDANT CORPORATION, et al., Defendants-Appellees. ____________ Appeal from the United States District Court for the Southern District of Indiana, Indianapolis Division. No. 05–CV–1009—Larry J. McKinney, Chief Judge. ____________ ARGUED APRIL 10, 2007—DECIDED JUNE 5, 2007 ____________

Before BAUER, POSNER, and RIPPLE, Circuit Judges. POSNER, Circuit Judge. This is a class action on behalf of participants and beneficiaries in a pension plan for employ- ees of Guidant Corporation. A manufacturer of cardiovas- cular devices, Guidant was bought last year by Boston Scientific, which paid for each share of Guidant stock $42.28 in cash plus 1.6799 shares (worth $37.78 at the time, as each share was worth $22.49) of stock in Boston Scien- tific, for a total value of $80.06. The plan’s portfolio in- cluded stock in Guidant held by an ESOP (employee stock 2 No. 06-3752

ownership plan), and the suit claims that the pension plan’s fiduciaries acted imprudently in failing to dispose of that stock between October 1, 2004, and November 3, 2005. The fiduciaries are various employees and board members of Guidant, all of whom were under the company’s control (as ERISA permits, see 29 U.S.C. §§ 1102(c)(1), 1103(a)(1); Geddes v. United Staffing Alliance Employee Medical Plan, 469 F.3d 919, 923–24 (10th Cir. 2006); U.S. Department of Labor, “Meeting Your Fiduciary Responsibilities,” www.dol.gov/ebsa/publications/fiduciaryresponsibility .html (visited May 17, 2007)), as was the ESOP. So for the sake of simplicity we shall pretend that Guidant is the only defendant and the only fiduciary. October 2004 to November 2005 was a period, prior to Boston Scientific’s acquisition of Guidant (which took place in April 2006), when according to the complaint the price of Guidant stock was inflated by a fraud committed by the company’s management. The alleged fraud consisted of the concealment of information concerning defects in the company’s implantable defibrillators, which accounted for nearly half its revenues. Very shortly after Boston Scien- tific’s acquisition of Guidant, the full gravity of Guidant’s problems came to light and the revelation contributed to the drop in the price of Boston Scientific stock from $22.49 when Boston Scientific bought Guidant to $16.33 on May 3 of this year. The district court dismissed the complaint on the ground that the named plaintiffs have no “standing” to bring this suit because they retired from Guidant and cashed out their pension benefits before the filing of the amended complaint, and so ceased to be participants in the pension plan. The lawyers for the class could, to keep the class action alive, have substituted as named plaintiffs members of the class who remained participants in the plan—current No. 06-3752 3

employees. But being unwilling to abandon the claims of class members in the situation of the named plaintiffs, they decided instead to appeal the district court’s ruling. To make the issue of “standing,” as the parties call it, intelligible, we must say a bit more about the plan and the allegations. The plan is a defined-contribution plan, meaning that it does not specify the pension benefits to which participants are entitled. Rather, it establishes retirement accounts for each participant and a scheme for determining the character, amount, timing, etc., of contri- butions to those accounts by employer and employee. When a participant retires, his pension benefit is simply the balance in his account. Contributions to the Guidant pension plan and hence to the retirement accounts were to come from both a 401(k) plan and the ESOP, the former funded by employee contributions and matching employer contributions and the latter funded by Guidant’s issuing common stock to the ESOP usually amounting to five percent of the employee’s monthly salary. Apparently the ESOP component of the pension plan accounted for most of the value in most of the retirement accounts. In December 2004, Guidant agreed to be sold to Johnson & Johnson for $76 a share. But before the deal could be consummated, problems with Guidant’s products came to light. It was forced to recall hundreds of thousands of defibrillators and pacemakers; Johnson & Johnson began to get cold feet; and the Attorney General of New York filed a fraud complaint (still pending) against Guidant. (On Guidant’s woes, see Barry Meier & Andrew Ross Sorkin, “Price Tag of Guidant Is Lowered,” N.Y. Times, Nov. 16, 2005, at C1.) But although Guidant was thus in trouble toward the end of the period (which, remember, ran from October 2004 to November 2005) in which the plaintiffs 4 No. 06-3752

contend that the pension plan’s fiduciaries should have disposed of the plan’s Guidant stock, it bounced back shortly afterwards, rising steadily until the company’s sale to Boston Scientific in April 2006 (after Johnson & Johnson, having earlier lost interest, made a new offer, of $71 per share) for, as we said, a total consideration of $80.06 a share. (See accompanying charts graphing Guidant’s share price from the beginning of 2004 to the acquisition by Boston Scientific, and Boston Scientific’s share price thereafter.). No. 06-3752 5

Had the pension plan been divested of its Guidant stock no later than November 2005, as the plaintiffs claim it should have been, the members of the class would have missed out on the sale of Guidant to Boston Scientific. It is unlikely that they would have done better from whatever substitute investment Guidant would have put them in. Even after Boston Scientific’s stock tanked following the acquisition of Guidant, anyone who owned Guidant stock at the time of the acquisition received $42.28 per share in cash plus 1.6799 shares of Boston Scientific worth $27.43 as of May 3 of this year. The total of $69.71 exceeds the price of Boston Scientific on the last day of the class period ($57.57) and also the revised offer of $63 per share that Johnson & Johnson submitted twelve days after the class period ended. And it falls only slightly short of the $71 that Johnson & Johnson ultimately offered—an offer that the plaintiffs claim was inflated by that company’s ignorance of the fraudulent overvaluation of Guidant. So, had there 6 No. 06-3752

been no fraud, the price that Johnson & Johnson and Boston Scientific would have offered for a share of Guidant stock would have been less than either the $80.06 that Boston Scientific eventually paid or the $69.71 in cash and stock that shareholders in Guidant when it was acquired by Boston Scientific still have. But whether the class was injured by Guidant’s alleged imprudence in its capacity as the plan fiduciary (or whether, for that matter, Guidant was imprudent) has not been considered by the district court or raised as an issue in this appeal, and so we shall not try to resolve it. The issue that has been raised and pressed is whether the plaintiffs are within the group of persons who are autho- rized to seek relief under ERISA. Section 502(a)(2) of the statute authorizes a participant in an ERISA-governed plan to sue “for appropriate relief under section 1109 [of Title 29].” 29 U.S.C. § 1132(a)(2). Section 1109 makes ERISA fiduciaries personally liable for breaches of their fiduciary duties. The named plaintiffs, however, cashed out of the plan during the course of the suit.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mello v. Sara Lee Corp.
431 F.3d 440 (Fifth Circuit, 2005)
Langbecker v. Electronic Data Systems Corp.
476 F.3d 299 (Fifth Circuit, 2007)
Massachusetts Mutual Life Insurance v. Russell
473 U.S. 134 (Supreme Court, 1985)
Clarke v. Securities Industry Assn.
479 U.S. 388 (Supreme Court, 1987)
Firestone Tire & Rubber Co. v. Bruch
489 U.S. 101 (Supreme Court, 1989)
Mertens v. Hewitt Associates
508 U.S. 248 (Supreme Court, 1993)
Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Vartanian v. Monsanto Company
14 F.3d 697 (First Circuit, 1994)
Richard P. Kuntz v. Nat J. Reese
785 F.2d 1410 (Ninth Circuit, 1986)
Patricia Burdett v. Robert S. Miller
957 F.2d 1375 (Seventh Circuit, 1992)
Tom Waits v. Frito-Lay, Inc. Tracy-Locke, Inc.
978 F.2d 1093 (Ninth Circuit, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
Harzewski, Erica v. Guidant Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/harzewski-erica-v-guidant-corporation-ca7-2007.